Swedish medical software developer RaySearch Laboratories AB (publ) reported a decline in second-quarter 2026 sales, attributing the drop to delays in the U.S. market.
The company disclosed the sales decline in an earnings call transcript on Tuesday, though it did not provide specific revenue figures. RaySearch attributed the shortfall to postponed or deferred orders in the United States, which it identified as a key revenue driver for its oncology-focused software solutions.
Chief Executive Officer Johan Kreuger acknowledged the impact of the delays during the call, stating that while U.S. operations remained a priority, timing uncertainties had affected near-term performance. The company emphasized that its long-term growth strategy, including expansion in Europe and Asia, remained unchanged.
Analysts monitoring the company’s trajectory noted that RaySearch’s reliance on the U.S. market had been a recurring theme in recent quarters. The delays come amid broader discussions about healthcare spending trends and procurement cycles in the sector.
RaySearch, listed on the Nasdaq Stockholm exchange, did not revise its full-year guidance during the call but reiterated its commitment to advancing its product pipeline. The company’s software is widely used in radiation therapy planning and oncology information systems.
The earnings call transcript did not include specific financial metrics beyond the sales decline, and no further details were provided regarding the expected duration or scale of the U.S. delays.
